Ulocuplumab
- Generic Name
- Ulocuplumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1375830-34-4
- Unique Ingredient Identifier
- 7KNP87L4X4
- Background
Ulocuplumab is under investigation in Solid Tumor.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 13
- Registration Number
- NCT03225716
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT02666209
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 61
- Registration Number
- NCT02472977
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States
🇺🇸University Of Colorado Hosp, Aurora, Colorado, United States
🇺🇸Columbia University Medical Center (Cumc), New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath